BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24077220)

  • 1. Role of matrix metalloproteinase-10 in the BMP-2 inducing osteoblastic differentiation.
    Mao L; Yano M; Kawao N; Tamura Y; Okada K; Kaji H
    Endocr J; 2013; 60(12):1309-19. PubMed ID: 24077220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Tmem119 and the bone morphogenetic protein pathway in the commitment of myoblastic into osteoblastic cells.
    Tanaka K; Inoue Y; Hendy GN; Canaff L; Katagiri T; Kitazawa R; Komori T; Sugimoto T; Seino S; Kaji H
    Bone; 2012 Jul; 51(1):158-67. PubMed ID: 22579779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
    Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
    J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of G
    Ebner JK; König GM; Kostenis E; Siegert P; Aktories K; Orth JHC
    Bone; 2019 Oct; 127():592-601. PubMed ID: 31376533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
    J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
    Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
    Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of matrix metalloproteinase-13 and tissue inhibitor of matrix metalloproteinase-1 gene expression by WNT3A and bone morphogenetic protein-2 in osteoblastic differentiation.
    Nakashima A; Tamura M
    Front Biosci; 2006 May; 11():1667-78. PubMed ID: 16368545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of osteoglycin in the linkage between muscle and bone.
    Tanaka K; Matsumoto E; Higashimaki Y; Katagiri T; Sugimoto T; Seino S; Kaji H
    J Biol Chem; 2012 Apr; 287(15):11616-28. PubMed ID: 22351757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
    Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
    J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
    Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the osteoinductive factors, Tmem119 and BMP-2, and the ER stress response PERK-eIF2α-ATF4 pathway in the commitment of myoblastic into osteoblastic cells.
    Tanaka K; Kaji H; Yamaguchi T; Kanazawa I; Canaff L; Hendy GN; Sugimoto T
    Calcif Tissue Int; 2014 Apr; 94(4):454-64. PubMed ID: 24362451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAM5C is a soluble osteoblast differentiation factor linking muscle to bone.
    Tanaka K; Matsumoto E; Higashimaki Y; Sugimoto T; Seino S; Kaji H
    Biochem Biophys Res Commun; 2012 Feb; 418(1):134-9. PubMed ID: 22245424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva.
    Shi S; Cai J; de Gorter DJ; Sanchez-Duffhues G; Kemaladewi DU; Hoogaars WM; Aartsma-Rus A; 't Hoen PA; ten Dijke P
    PLoS One; 2013; 8(7):e69096. PubMed ID: 23861958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.
    Yamamoto R; Matsushita M; Kitoh H; Masuda A; Ito M; Katagiri T; Kawai T; Ishiguro N; Ohno K
    J Bone Miner Metab; 2013 Jan; 31(1):26-33. PubMed ID: 23011467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potential modifiers of Runx2/Cbfa1 activity in C2C12 cells in response to bone morphogenetic protein-7.
    Gu K; Zhang L; Jin T; Rutherford RB
    Cells Tissues Organs; 2004; 176(1-3):28-40. PubMed ID: 14745233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.